Related Experiment Video
Updated: Aug 15, 2026
Quantification of Neurovascular Protection Following Repetitive Hypoxic Preconditioning and Transient Middle Cerebral Artery Occlusion in Mice
Published on: May 4, 2015
Methodological quality of animal studies on neuroprotection in focal cerebral ischaemia
H Bart van der Worp1, Peter de Haan, Erik Morrema
1Dept. of Neurology, HP G 03.228, University Medical Centre Utrecht, 85500, 3508 GA Utrecht, The Netherlands. h.b.vanderworp@neuro.azu.nl
Background:
The recurrent failure of apparently promising neuroprotective drugs to improve outcome in trials of patients with acute ischaemic stroke may partially be explained by over-optimistic conclusions about efficacy as a result of methodological shortcomings in preclinical studies. We assessed the methodological quality of animal studies of five different neuroprotective agents that have been tested in 21 clinical trials including a total of more than 12,000 patients with acute ischaemic stroke.
Methods:
We performed a literature search restricted to full publications on the effects of clomethiazole, gavestinel, lubeluzole, selfotel, or tirilazad mesylate on infarct volume or functional outcome in animal models of acute focal cerebral ischaemia. We used a rating scale to assess the methodological quality of the included studies. One point was attributed to each of 10 items. A score of 4 to 6 points was considered "medium" and a score above 7 "high."
Results:
A total of 45 articles were included. The median score on the methodological quality index was 3; 18 studies had a medium score and one a high score. Randomised treatment allocation was mentioned in 19 studies (42 %), blinded administration of study medication in 10 (22 %), and blinded outcome assessment in 18 (40 %). The study drug was administered at a median of 10 min (range, -60 to 360 min) after the onset of ischaemia.
Conclusion:
The evidence for neuroprotective efficacy that formed the basis for initiating the 21 trials was obtained in animal studies with a methodological quality that would, in retrospect, not justify such a decision. More rigorous preclinical study methodology may lead to more reliable and reproducible results.
Insights
Preclinical studies for neuroprotective drugs in acute ischemic stroke often had methodological shortcomings. This poor quality research led to over-optimistic conclusions, failing to improve patient outcomes in clinical trials.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Trials
Background:
- Numerous neuroprotective drugs for acute ischemic stroke have failed in clinical trials.
- Methodological weaknesses in preclinical animal studies may contribute to over-optimistic efficacy conclusions.
- This study evaluates the methodological quality of animal studies for five neuroprotective agents tested in human trials.
Purpose of the Study:
- To assess the methodological quality of preclinical animal studies for neuroprotective drugs in acute ischemic stroke.
- To determine if the quality of these studies justifies their use in initiating clinical trials.
- To identify potential reasons for the recurrent failure of these drugs in patient trials.
Main Methods:
- Literature search for full publications on five specific neuroprotective agents (clomethiazole, gavestinel, lubeluzole, selfotel, tirilazad mesylate).
- Assessment of methodological quality using a 10-item rating scale (medium score: 4-6, high score: >7).
- Inclusion criteria focused on infarct volume or functional outcome in animal models of acute focal cerebral ischemia.
Main Results:
- 45 articles were included, with a median methodological quality score of 3.
- Only one study achieved a high methodological score; 18 had medium scores.
- Key methodological elements like randomized allocation (42%), blinded drug administration (22%), and blinded outcome assessment (40%) were inconsistently reported.
Conclusions:
- The preclinical evidence supporting the initiation of 21 clinical trials was of insufficient methodological quality.
- Retrospective analysis suggests these studies would not have justified the decision to proceed to human trials.
- Implementing more rigorous preclinical study designs is crucial for generating reliable and reproducible results in neuroprotection research.
